Analyst Reco. Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
24.88 ^USD	+0.32%		+3.19%	-8.60%

May. 07	Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates	MT
May. 07	Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	Apr. 04	MT
Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing	Apr. 04	MT
Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating	Feb. 28	MT
RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk	Feb. 28	MT
Wedbush Adjusts Beam Therapeutics' Price Target to $57 From $48, Keeps Outperform Rating	Feb. 27	MT
JPMorgan Upgrades Beam Therapeutics to Overweight From Neutral, Raises Price Target to $40 From $38	Jan. 29	MT
BofA Securities Downgrades Beam Therapeutics to Neutral From Buy, Price Target is $35	Dec. 15	MT
Jefferies Downgrades Beam Therapeutics to Hold From Buy, Cuts Price Target to $30 From $75	Dec. 08	MT
Cantor Fitzgerald Lowers Price Target on Beam Therapeutics to $32 From $56, Maintains Overweight Rating	23-10-17	MT
Credit Suisse Adjusts Beam Therapeutics' Price Target to $47 From $46, Keeps Neutral Rating	23-08-09	MT
Citigroup Adjusts Beam Therapeutics Price Target to $56 From $60, Maintains Buy Rating	23-08-09	MT
RBC Cuts Beam Therapeutics' Price Target to $32 From $42, Keeps Sector Perform Speculative Risk Rating	23-07-07	MT
Citigroup Adjusts Price Target on Beam Therapeutics to $60 From $62, Keeps Buy Rating	23-05-11	MT
Barclays Adjusts Price Target on Beam Therapeutics to $41 From $45, Keeps Equalweight Rating	23-05-11	MT
RBC Cuts Price Target on Beam Therapeutics to $42 From $50, Maintains Sector Perform, Speculative Risk Rating	23-05-11	MT
Bernstein Initiates Beam Therapeutics at Market Perform With $37 Price Target	23-03-21	MT
Wells Fargo Adjusts Price Target on Beam Therapeutics to $105 From $125, Keeps Overweight Rating	23-03-01	MT
Cantor Fitzgerald Starts Beam Therapeutics at Overweight With $62 Price Target	23-02-01	MT
SVB Securities Trims Price Target on Beam Therapeutics to $77 From $81, Maintains Outperform Rating	23-01-23	MT
BMO Capital Upgrades Beam Therapeutics to Outperform From Market Perform, Raises Price Target to $66 From $61	22-12-20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Beam CEO Andy Bromberg: Bitcoin ETFs a financialisation away from the original essence of crypto

January 30, 2024 at 02:21 pm EST